[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
3. Shimamoto T, Hayashi S, Ando K, Yguchi M, Miyazawa K, Kimura Y, Mukai K, Serizawa H, Ohyashiki K: Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy. Am J Hematol; 2001 Jan;66(1):49-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy.
  • We report a patient with anaplastic large-cell lymphoma (ALCL) who has been given immunosuppressive therapy for Evans syndrome for 10 years.
  • He was admitted with spike fever, intra-abdominal lymphadenopathy, and multiple liver masses.
  • Examination of biopsy specimens obtained by para-aortic lymph nodes and liver masses resulted in a diagnosis of ALCL.
  • He was treated with combination chemotherapy (ABVD regimen), achieving complete remission.
  • Myelodysplasia and serum IL-6 and VEGF also normalized after treatment.
  • We assumed that ALCL resulted from long-term immunosuppressive therapy and that the up-regulation of IL-6 and VEGF played a role in pathogenesis of this type of lymphoma.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Cyclosporine / adverse effects. Endothelial Growth Factors / blood. Immunosuppressive Agents / adverse effects. Interleukin-6 / blood. Lymphokines / blood. Lymphoma, Large B-Cell, Diffuse / drug therapy. Myelodysplastic Syndromes / etiology. Pancytopenia / drug therapy. Prednisolone / adverse effects
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bone Marrow / pathology. CD4-CD8 Ratio. Cell Lineage. Combined Modality Therapy. DNA, Neoplasm / analysis. DNA, Viral / analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Fever / etiology. Fibroblast Growth Factor 2 / blood. Gene Rearrangement, B-Lymphocyte. Humans. Immunocompromised Host. Inflammation. Lymph Nodes / pathology. Male. Middle Aged. Remission Induction. Splenectomy. Syndrome. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426493.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral; 0 / Endothelial Growth Factors; 0 / Immunosuppressive Agents; 0 / Interleukin-6; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone; ABVD protocol
  •  go-up   go-down


Advertisement
4. Kochi M, Fujii M, Kanamori N, Kaiga T, Takahashi T, Kobayashi M, Takayama T: Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma. Hepatogastroenterology; 2007 Jun;54(76):1285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma.
  • BACKGROUND/AIMS: There are many controversies regarding the treatment for primary gastric non-Hodgkin's lymphoma (PGL).
  • We hypothesized that preoperative chemotherapy and extensive surgery would improve patient survival in the treatment of early stage patients with PGL.
  • All patients received preoperative chemotherapy, i.e.
  • Upon the completion of chemotherapy, the extensive surgery including total gastrectomy, splenectomy, cholecystectomy, and paraaortic lymphadenectomy were performed.
  • The response rates of preoperative chemotherapy and overall survival were analyzed.
  • In all patients, microscopic examinations did not reveal residual lymphoma cells in the resected stomach or lymph nodes.
  • Chemotherapy-related preoperative complications such as perforation or intestinal bleeding did not occur in any of the cases.
  • Postoperative complications developed in 30% (3/10) of patients and consisted of 2 pancreatic fistulas, 3 intra-abdominal abscesses, and 1 anastomotic leak.
  • CONCLUSIONS: Primary chemotherapy alone without surgery may produce complete remission in Stage IE-IIE PGL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Preoperative Care. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629090.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


5. Crysandt M, Neumann B, Das M, Engelbertz V, Bendel M, Galm O, Osieka R, Jost E: Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol; 2007 Dec;79(6):546-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
  • In the past decade, rituximab in combination with polychemotherapy has become the standard approach in most patients with advanced CD20-positive B-cell lymphoma.
  • In mantle cell lymphoma (MCL), follicular lymphoma and diffuse large B-cell lymphoma, rituximab has been used as monotherapy and in combination with various chemotherapy regimens in different treatment situations.
  • Here, we report a 64-yr-old woman who was previously treated with three different chemotherapy regimens for stage IV MCL.
  • The patient's general status declined and she developed massive ascites as the dominant clinical problem.
  • Local, intraperitoneal administration of rituximab was initiated as an experimental treatment approach.
  • After 11 doses of rituximab, the general status of the patient improved significantly, ascites resolved completely and computed tomography (CT) scans demonstrated a partial remission of intra-abdominal lymph nodes and splenomegaly.
  • Furthermore, we observed a regression of mediastinal lymph nodes, pleural effusion and centrocytes in peripheral blood as well as improvement of anaemia.
  • The response to the experimental treatment has maintained for more than 6 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Ascites / drug therapy. Infusions, Parenteral / methods. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Anemia / drug therapy. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Rituximab. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903214.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


6. Tanaka Y, Kurata M, Togami K, Fujita H, Watanabe N, Matsushita A, Maeda A, Nagai K, Sada A, Matsui T, Takahashi T: Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. Int J Hematol; 2006 Feb;83(2):152-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.
  • He had developed intra-abdominal non-Hodgkin's lymphoma and in 1992 had received 3 courses of combination chemotherapy with doxorubicin (Adriamycin), cyclophosphamide, vincristine, methotrexate, bleomycin, and prednisolone.
  • The patient was orally given prednisolone (10 mg/day) and cyclophosphamide (50 mg/day) as HES treatment without a subsequent improvement of the eosinophilia.
  • Treatment with imatinib mesylate (300 mg/day) promptly brought about complete remission.
  • Although a number of similar eosinophilic cases have been reported, our patient may be the first such patient with a history of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hypereosinophilic Syndrome / etiology. Oncogene Proteins, Fusion / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. mRNA Cleavage and Polyadenylation Factors / genetics
  • [MeSH-minor] Adult. Benzamides. Chronic Disease. Humans. Imatinib Mesylate. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Male. Molecular Sequence Data. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Feb 15;87(4):1416-22 [8608231.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):584-8 [15148104.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4714-6 [12595304.001]
  • [Cites] Leukemia. 2004 Apr;18(4):734-42 [14973504.001]
  • [Cites] Haematologica. 2004 Feb;89(2):236-7 [15003901.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1577-8 [12047970.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):881-4 [12127565.001]
  • [Cites] Br J Haematol. 2003 Jul;122(2):173-9 [12846884.001]
  • [Cites] MedGenMed. 2001 Sep 07;3(5):9 [11698916.001]
  • [Cites] Leuk Lymphoma. 1998 Mar;29(1-2):17-26 [9638972.001]
  • [Cites] Blood. 2003 May 1;101(9):3391-7 [12506022.001]
  • [Cites] Hematol J. 2003;4(6):410-2 [14671612.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1996 Oct;95(1):2-9 [8857931.001]
  • [Cites] Blood. 2004 Jan 15;103(2):473-8 [14504092.001]
  • [Cites] Blood. 1988 Feb;71(2):403-14 [3337904.001]
  • [Cites] Blood. 2003 Jun 15;101(12 ):4660-6 [12676775.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S79-80 [15036947.001]
  • [Cites] Medicine (Baltimore). 1975 Jan;54(1):1-27 [1090795.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):477-80 [14986065.001]
  • [Cites] N Engl J Med. 1994 Feb 24;330(8):535-8 [8302319.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):75-7 [15293573.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):51-7 [14676627.001]
  • (PMID = 16513534.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / FIP1L1-PDGFRA fusion protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


7. Chung KM, Chuang SS, Hwang WS, Lee PS, Li CY: High dose chemotherapy and allogenic peripheral blood stem cell transplantation for multiple myeloma evolving from intra-abdominal plasmacytoma. Zhonghua Yi Xue Za Zhi (Taipei); 2002 Nov;65(11):557-60
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose chemotherapy and allogenic peripheral blood stem cell transplantation for multiple myeloma evolving from intra-abdominal plasmacytoma.
  • We present an unusual case of intra-abdominal plasmacytoma in a young woman which was misdiagnosed and treated as T cell lymphoma initially.
  • High dose chemotherapy followed by allogeneic peripheral stem cell blood transplantation (allo-PBSCT) was given.
  • [MeSH-major] Abdominal Neoplasms / complications. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / therapy. Plasmacytoma / complications
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Melphalan / administration & dosage. Prednisolone / administration & dosage. Transplantation, Homologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12583522.001).
  • [ISSN] 0578-1337
  • [Journal-full-title] Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi (Taipei)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


8. Brihi E, Akoum R, Saade M, Chahine G: Abdominal irradiation after chemotherapy in non-Hodgkin's lymphoma: review of 32 patients. Mol Immunol; 2003 Jul;39(17-18):1121-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal irradiation after chemotherapy in non-Hodgkin's lymphoma: review of 32 patients.
  • OBJECTIVE: Our objective is to evaluate the efficacy and toxicity of abdominal irradiation after chemotherapy in the management of Non-Hodgkin's Lymphoma.
  • METHODS: Between 1982 and 1997, 32 patients underwent abdominal irradiation; as adjuvant treatment to chemotherapy (5 patients), as curative treatment for residual mass (9 patients) or as salvage treatment for refractory disease (18 patients).
  • The dose administered to the total abdomen was 18-20 Gy at the rate of 1.5-1.8 Gy per daily fraction followed by a boost to gross disease up to a total dose of 40-44 Gy.
  • The local control was significantly better in patients with follicular type lymphoma than in those with the diffuse type.
  • CONCLUSION: Adjuvant whole abdominal irradiation is feasible and efficient in patients with Non-Hodgkin's Lymphoma at high risk of intra-abdominal failure.
  • Abdominal irradiation for residual disease consolidates remission with acceptable toxicity.
  • Salvage radiotherapy for abdominal failure after chemotherapy provides significant palliation and prolongation of survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Abdomen. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Safety. Survival Rate. Treatment Failure. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12835089.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Ugur H, Tacyildiz N, Yavuz G, Unal E, Sayili A, Emir S, Kansu A, Kuloglu Z, Bahar K: Obstructive jaundice: an unusual initial manifestation of intra-abdominal non-Hodgkin lymphoma in a child. Pediatr Hematol Oncol; 2006 Jan-Feb;23(1):87-90
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice: an unusual initial manifestation of intra-abdominal non-Hodgkin lymphoma in a child.
  • Although surgical drainage is one of the initial treatment choices in some cases, usually lymphomatous masses rapidly response to chemotherapy and jaundice decreases due to regression of the mass, without any surgical procedure.
  • Histological examination of the specimen, which was taken from the mass by endoscopic biopsy, revealed Burkitt lymphoma infiltrating the duodenum.
  • Chemotherapy including cyclophosphamide was started immediately.
  • In conclusion, biliary tract obstruction due to non-Hodgkin lymphoma can be effectively treated with chemotherapy alone without any surgical procedure.
  • [MeSH-major] Abdominal Neoplasms / pathology. Jaundice, Obstructive / etiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / pathology. Cyclophosphamide / therapeutic use. Duodenal Neoplasms / pathology. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326418.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


10. Culić S, Kuljis D, Armanda V, Jankovic S: Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatr Blood Cancer; 2007 Sep;49(3):332-5
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins.
  • We present the case of an 18-year-old female with Burkitt lymphoma involving the intra-abdominal and inguinal lymph nodes.
  • Chemotherapy and anticoagulant treatment resulted in mild thrombocytopenia and a prolonged prothrombin time, respectively, which exacerbated postoperative bleeding following surgical removal of a deep inguinal necrosis.
  • The patient has since achieved complete remission and subsequent antithrombotic therapy has resolved the vascular occlusion.
  • [MeSH-major] Factor VIIa / therapeutic use. Femoral Vein. Iliac Vein. Postoperative Hemorrhage / drug therapy. Venous Thrombosis / surgery
  • [MeSH-minor] Adolescent. Anticoagulants / adverse effects. Antineoplastic Agents / adverse effects. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy. Female. Heparin, Low-Molecular-Weight / adverse effects. Humans. Recombinant Proteins / therapeutic use. Thrombocytopenia / chemically induced. Thrombocytopenia / complications

  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16514611.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; 0 / Recombinant Proteins; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


11. Okur FV, Oguz A, Karadeniz C, Citak C, Poyraz A, Boyunaga O: Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol; 2006 Jan-Feb;23(1):25-31
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma.
  • The authors describe a 6-year-old boy diagnosed with mediastinal Burkitt lymphoma with tumor invasion into bone marrow and both kidneys.
  • After receiving chemotherapy according to NHL BFM-95 protocol for the high-risk disseminated lymphoma, the patient reached complete remission.
  • He relapsed in the mediastinum at 5 months from the diagnosis.
  • Autologous stem cell transplantation could not be performed because of unresponsiveness to cytoreductive chemotherapy.
  • Twenty-three days after the last chemotherapy course, he received rituximab at a dose of 375 mg/m2 by intravenous infusion weekly, for a total of 8 dose.
  • However, multiple intra-abdominal metastatic lesions were detected at the end of the therapy.
  • He died because of disease progression, 11 months after the diagnosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / secondary. Child. Drug Resistance, Neoplasm. Fatal Outcome. Humans. Kidney Neoplasms / secondary. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Neoplasm Invasiveness. Palliative Care. Recurrence. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326409.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


12. Turial S, Karabul N, Gutjahr P, Engel V, Bierschock S, Schier F: Ovarian tumours: late extramedullary recurrence of acute leukaemia. Eur J Pediatr Surg; 2009 Jun;19(3):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local therapy such as irradiation or extensive surgical resection of the mass is ineffective and unnecessary.
  • Treatment was initiated according to the CoALL 82-protocol.
  • At the age of 11, the girl presented with a huge abdominal mass.
  • Chemotherapy and low-dose radiotherapy succeeded in shrinking the tumour mass, making it operable.
  • Subsequently, she developed a painless abdominal tumour.
  • Laparoscopic lymph node staging was performed and biopsies were taken.
  • Chemotherapy was initiated according to the BFM protocol for ALL recurrence.
  • CONCLUSION: Because we experienced favourable results with laparoscopic biopsy in our patients, we are of the opinion that laparoscopy-assisted biopsies are well suited for the management of intra-abdominal tumours in systemic malignant disease.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Humans. Ovariectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212934.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Cennamo A, Falsetto A, Tolomeo R, Cioffi E, Gallo G, De Pascale V: The first-reported case of diffuse purulent peritonitis in a patient with retroperitoneal Hodgkin disease (etiopathogenetic hypotheses). Ann Ital Chir; 2001 Nov-Dec;72(6):697-701
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of purulent diffuse peritonitis in a patient who was affected by Hodgkin lymphoma, with no evidence of other abdominal diseases.
  • This is a 54 y. old. white male who was admitted to our department with a history of asthenia, recurrent fever, dysphagia and abdominal pain.
  • In the plain abdominal radiology pneumoperitoneum was evident.
  • Duodenal perforation suspicion was confirmed by anamnesis and plain radiology which showed the presence of intra abdominal air.
  • A postoperative abdominal CT scan and histology of a biopsy taken during the second surgical operation showed a retroperitoneal Hodgkin lymphoma, which went to remission after chemotherapy.
  • Considering the two simultaneous clinical manifestations (retroperitoneal Hodgkin lymphoma and peritonitis), we made two pathogenetic hypotheses: a) The retroperitoneal disease produced lymphatic stagnation and peritoneal transudation, which then was infected;.
  • b) The abnormal lymph nodes were infected and the abdominal cavity was contaminated from retroperitoneum from blood/lymphatic stream or by contiguity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12061221.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Chow H, Lim CH, Ong W, Ng HJ: Incidence of ifosfamide-induced neurotoxicity in lymphoma patients receiving fractionated ICE-based chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):6677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of ifosfamide-induced neurotoxicity in lymphoma patients receiving fractionated ICE-based chemotherapy.
  • : 6677 Background: Ifosfamide-induced neurotoxicity is a treatment-related complication that is increasingly being reported.
  • METHODS: We reviewed all Hodgkin's and Non-Hodgkin's lymphoma patients who received fractionated ICE (D1-3: ifosfamide 2g/m<sup>2</sup> over 2h with an equivalent dose of mesna over 12h, carboplatin [AUC=5 divided equally between 3 days; max=800mg] over 1h, etoposide 75mg/m<sup>2</sup> over 2h; cycles were repeated q28 days) +/- rituximab.
  • Patients who experienced any neurologic symptom prior to initiation of chemotherapy were excluded.
  • Treatment of symptoms involved the use of methylene blue alone in 2 cases and thiamine combined with methylene blue in 1 case.
  • Previously identified risk factors such as renal and hepatic impairment, prior cisplatin, prior cranial radiation, albumin < 30g/L, pelvic/intra-abdominal involvement, and stage and type of disease were analyzed.
  • CONCLUSIONS: Fractionated ICE-based chemotherapy is associated with a high incidence of ifosfamide-induced neurotoxicity in relapsed or refractory lymphoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Alkhunaizi AM, Daabil RA, Dawamneh MF: Acute kidney injury secondary to lymphomatous infiltration and the role of kidney biopsy. Saudi Med J; 2008 Dec;29(12):1808-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 47-year-old male patient who developed acute kidney injury requiring hemodialysis, associated with massive enlargement of both kidneys.
  • A part from intra-abdominal lymphadenopathy, there was no other organ or lymph node involvement.
  • A kidney biopsy established the diagnosis of non-Hodgkin's lymphoma.
  • The patient received chemotherapy with good response.
  • This case demonstrates that the kidney could be the primary organ involved in non-Hodgkin's lymphoma.
  • In addition, we have shown that renal biopsy is adequate to make a diagnosis of lymphoma without the need to do more invasive testing.
  • [MeSH-major] Acute Kidney Injury / etiology. Acute Kidney Injury / pathology. Kidney / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082238.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


16. Sfaxi M, Bouzouita A, Bouasker I, Kourda N, Ben Slama MR, Ben Jilani Baltaji S, Chebil M: [Primary bilateral adrenal T-cell lymphoma. A case report rarer than B-cell lymphoma]. Ann Endocrinol (Paris); 2008 Jun;69(3):249-53
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary bilateral adrenal T-cell lymphoma. A case report rarer than B-cell lymphoma].
  • [Transliterated title] Lymphome surrénalien primitif bilatéral de phénotype T. Un cas clinique beaucoup plus rare que le lymphome B.
  • Primary adrenal lymphoma is a rare condition.
  • Adrenal lymphoma is often bilateral and in most of the cases of B-cell type.
  • T-cell lymphoma is exceptional.
  • We report a case of a 70-year-old man who was admitted for acute adrenal insufficiency due to primary bilateral adrenal T-cell lymphoma.
  • He had corticotherapy and surgical exploration for intra-abdominal sepsis.
  • Clinical features and imaging are not specific. (18)F-FDG PET Scan is an excellent mean to detect malignant tumor of adrenal gland.
  • The standard treatment is chemotherapy.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging
  • [MeSH-minor] Aged. Fatal Outcome. Fluorodeoxyglucose F18. Humans. Immunohistochemistry. Incidence. Lymphoma, B-Cell / epidemiology. Male. Multiple Organ Failure. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455145.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • A 66-year-old man was admitted to our hospital because of an intra-abdominal tumor and pleural effusion (PE).
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • In general, gastric MALT lymphoma cells have a tendency to differentiate into plasma cells.
  • In this article, we show that the cell character of API-2/MLT-positive MALT lymphoma is preserved even when the cells are disseminated.
  • This is the first published case, to our knowledge, in which two differentiation stages of MALT lymphoma cells infiltrating into PE have been confirmed by flow cytometric analysis.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Oncogene Proteins, Fusion / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


19. Lefor AT: Laparoscopic interventions in lymphoma management. Semin Laparosc Surg; 2000 Jun;7(2):129-39
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic interventions in lymphoma management.
  • The role of the surgeon in the care of the patient with lymphoma is limited mostly to obtaining a diagnosis.
  • Laparoscopy can play a significant role in the care of the patient requiring accurate intra-abdominal staging.
  • The staging procedure is conducted in a fashion identical to the open procedure, including multiple liver biopsies, a splenectomy, and multiple lymph node biopsies.
  • Patients with non-Hodgkin's lymphoma almost never require staging, and laparoscopy may play a role in obtaining tissue for diagnosis in a small fraction of patients.
  • Patients with Hodgkin's disease who have diffuse disease (stages III and IV) never need staging because they will all receive chemotherapy.
  • Likewise, patients with limited disease (stage I) are usually treated with radiation therapy alone.
  • The laparoscopic approach to this procedure may afford benefits to the patient including decreased hospitalization, morbidity, and reduced delays in obtaining definitive treatment.
  • [MeSH-major] Hodgkin Disease / pathology. Laparoscopy. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11320483.001).
  • [ISSN] 1071-5517
  • [Journal-full-title] Seminars in laparoscopic surgery
  • [ISO-abbreviation] Semin Laparosc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


20. Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL: Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg; 2010 Jul;20(4):234-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel obstruction after treatment of intra-abdominal tumors.
  • BACKGROUND: Tumors of the solid viscera are one of the most common types of pediatric malignancies.
  • Due to the intra-abdominal location of many of these neoplasms, laparotomy and/or bowel resection are often necessary, predisposing patients to postoperative intestinal obstruction.
  • Additionally, chemotherapy and radiation therapy may lead to acute and chronic bowel injury, also potentially predisposing these patients to postoperative bowel obstruction.
  • METHODS: A retrospective data analysis of all patients diagnosed with intra-abdominal Wilms' tumor, rhabdomyosarcoma, neuroblastoma, and Hodgkin's and non-Hodgkin's lymphoma in a single institution from 1997 to 2007 was conducted.
  • Data collected included demographic factors, operations, incidence of small bowel obstruction (SBO) and the use of adjuvant or neoadjuvant chemoradiation therapy.
  • Patients who developed SBO were compared to those who did not develop obstruction.
  • Data comparisons were analyzed statistically using Fisher's exact test, 2-tailed Student's t-Test, or chi-square proportional analysis with significance reported for p<0.05.
  • Mean age at diagnosis was 8.1+/-5.8 years.
  • Tumor distribution was as follows: Wilms' tumor: 56 (19%); non-Hodgkin's lymphoma: 71 (24%); Hodgkin's lymphoma: 64 (22%); rhabdomyosarcoma: 32 (11%); and neuroblastoma: 68 (24%).
  • CONCLUSION: Bowel obstruction is relatively uncommon after intra-abdominal malignancies in children.
  • Wilms' tumor, rhabdomyosarcoma and Burkitt's lymphoma appear to be associated with the highest risk of bowel obstruction.
  • [MeSH-major] Abdominal Neoplasms / surgery. Intestinal Obstruction / etiology. Laparotomy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496318.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Nakagawa Y, Miura K, Yamazaki T, Ishizuka H, Takei K, Sawada U, Kura Y, Hatta Y, Takeuchi J: A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance. Int J Hematol; 2010 Apr;91(3):530-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance.
  • Although great advancements have been witnessed in treatment results for hematopoietic tumors in recent years, development of secondary malignant tumors induced by anti-cancer drugs still remains a serious issue.
  • A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments.
  • Remission was induced by rituximab, administered at the time of relapse in 2001, followed by administration of 50 mg/day of CY since December 2001 for the prevention of relapse.
  • Anemia and thrombocytopenia developed around January 2003.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Cyclophosphamide / adverse effects. Lymphoma, Follicular / drug therapy. Myelodysplastic Syndromes / chemically induced

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Jun;15(6):963-70 [11417484.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4926-33 [15611507.001]
  • [Cites] Int J Hematol. 2002 Apr;75(3):302-4 [11999360.001]
  • [Cites] Baillieres Clin Haematol. 1996 Mar;9(1):57-85 [8730551.001]
  • [Cites] Med Oncol. 2005;22(4):407-10 [16260859.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1909-12 [11877259.001]
  • [Cites] Br J Haematol. 1996 Mar;92(3):696-8 [8616039.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Int J Hematol. 2001 Jul;74(1):86-9 [11530811.001]
  • [Cites] Blood. 1989 Oct;74(5):1491-8 [2676013.001]
  • (PMID = 20155339.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


22. Macák J, Mukensnábl P, Kawano N, Bobot L, Dusková M, Vácha P: [Intra-abdominal desmoplastic small-cell tumor of the peritoneum]. Cesk Patol; 2003 Apr;39(2):69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoplastic small-cell tumor of the peritoneum].
  • Intensive chemotherapy was applied but two patients died of generalisation.
  • The 22-year-old woman is alive but with clinical evidence of generalisation in the abdominal cavity.
  • The "classical" type of IDSRT was found in all the cases.
  • In one case the tumour consisted of round and oval cells resembling a lymphoma.
  • Many different tumour types, such as lymphoma, Ewing sarcoma/PNET, neuroblastoma, alveolar rhabdomyosarcoma, malignant mesothelioma must be excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874904.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


23. Velanovich V, Wollner I, Ajlouni M: Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies. J Gastrointest Surg; 2000 Sep-Oct;4(5):542-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies.
  • Staging laparoscopy avoids unnecessary laparotomies in patients with unresectable intra-abdominal malignancies.
  • However, the postoperative oncologic treatment of these patients has not been documented.
  • This study compares rates and timing of postoperative chemotherapy (ChT) and/or radiation therapy (XRT) in patients with unresectable intra-abdominal malignancies initially evaluated by staging laparoscopy (SL) or exploratory laparotomy (EL).
  • The records of patients surgically evaluated for esophageal, gastric, hepatobiliary, and pancreatic cancers or abdominal lymphoma were retrospectively reviewed.
  • Data gathered included type of exploration (SL or EL), resectability, whether postoperative cancer treatment was given (ChT, XRT, or both), and the time from surgery to the beginning of such treatment.
  • Sixteen of the SL patients (76%) and 25 of the EL patients (43%) received postoperative cancer treatment (P = 0.009).
  • The median number of days from surgery to postoperative cancer treatment was 13 days (range 5 to 41 days) for the SL group and 35 days (range 16 to 89 days) for the EL group (P = 0.0004).
  • We conclude that patients with unresectable intra-abdominal malignancies discovered by SL are more likely to receive postoperative ChT and/or XRT than patients surgically evaluated by EL.
  • Further studies to determine whether this better utilization of postoperative treatment results in better outcomes in these patients are needed.
  • [MeSH-major] Digestive System Neoplasms / therapy. Laparoscopy
  • [MeSH-minor] Biliary Tract Neoplasms / therapy. Combined Modality Therapy. Esophageal Neoplasms / therapy. Humans. Laparotomy. Palliative Care. Pancreatic Neoplasms / therapy. Retrospective Studies. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Dec;65(12):1143-9 [10597062.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):352-4 [7796006.001]
  • [Cites] Surg Endosc. 2000 Jan;14(1):16-21 [10653229.001]
  • [Cites] J Gastrointest Surg. 1999 Mar-Apr;3(2):111-7; discussion 117-8 [10457331.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):361-5 [9565114.001]
  • [Cites] Ann Surg. 1998 Aug;228(2):182-7 [9712562.001]
  • [Cites] Front Biosci. 1998 Nov 01;3:E193-203 [9792895.001]
  • [Cites] J Gastrointest Surg. 1997 May-Jun;1(3):245-50 [9834354.001]
  • [Cites] Cancer. 1982 May 1;49(9):1771-7 [6176313.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1127-9 [7648172.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):904-11 [1588370.001]
  • [Cites] Surgery. 1998 Oct;124(4):773-80; discussion 780-1 [9781001.001]
  • [Cites] Am Surg. 1998 Jul;64(7):686-92 [9655283.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):33-9 [9208958.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Endoscopy. 1993 Feb;25(2):143-50 [8491130.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):233-43 [10481116.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):752-5 [7683942.001]
  • [Cites] Surg Endosc. 1996 Oct;10 (10 ):970-3 [8864087.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):109-18 [10656381.001]
  • (PMID = 11077332.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ting JY, Chan SY, Lung DC, Ho AC, Chiang AK, Ha SY, Tsoi NN, Chan GC: Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy. J Pediatr Hematol Oncol; 2010 Aug;32(6):e238-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy.
  • We report 2 cases of unusual intra-abdominal Rhizopus microsporus infection in children with acute leukemia as a result of an unprecedented outbreak due to oral intake of contaminated allopurinol tablets and ready-to-eat food items.
  • Among the 2 patients, one of them survived after aggressive combined surgical, antifungal (AmBisome, Caspofungin, and Posaconazole) and iron chelation therapy.
  • [MeSH-major] Abdomen / microbiology. Antifungal Agents / therapeutic use. Immunocompromised Host. Iron Chelating Agents / therapeutic use. Mucormycosis / immunology. Mucormycosis / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / physiopathology. Male. Neutropenia / chemically induced. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Rhizopus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661158.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Iron Chelating Agents
  •  go-up   go-down


25. Ariad S, Benharroch D, Lupu L, Davidovici B, Dupin N, Boshoff C: Early peripheral lymph node involvement of human herpesvirus 8-associated, body cavity-based lymphoma in a human immunodeficiency virus-negative patient. Arch Pathol Lab Med; 2000 May;124(5):753-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early peripheral lymph node involvement of human herpesvirus 8-associated, body cavity-based lymphoma in a human immunodeficiency virus-negative patient.
  • Human herpesvirus 8 is also found in an unusual clinicopathologic form of body cavity-based B-cell lymphoma, which has been named primary effusion lymphoma (PEL) and occurs primarily in HIV-positive patients.
  • We describe a case of an HHV-8-associated lymphoma, with ascites, pleural effusion, and axillary lymphadenopathy in an HIV-negative patient.
  • The pleural fluid contained large atypical lymphoid cells and was suggestive of lymphoma but could not provide a conclusive diagnosis of PEL.
  • The lymph node contained groups of large anaplastic lymphoid cells.
  • Polymerase chain reaction for HHV-8 performed on the lymph node specimen was positive, establishing the diagnosis of PEL.
  • The patient did not respond to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone and progressively developed, massive intra-abdominal solid tumor formation.
  • To our knowledge, this is the first report of a case of PEL that demonstrates peripheral lymph node involvement at diagnosis and the first report of PEL in an Israeli patient.
  • [MeSH-major] HIV Seronegativity. Herpesvirus 8, Human / isolation & purification. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology
  • [MeSH-minor] Aged. Antigens, CD30 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Biopsy. Fatal Outcome. Humans. Male. Mucin-1 / analysis. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782162.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Mucin-1
  •  go-up   go-down


26. Sakakura C, Hagiwara A, Ikoma H, Hamada T, Taniwaki M, Horiike M, Yamagishi H: Massive lymphatic fluid leakage during laparoscopic lymphnode biopsy for abdominal malignancy. Hepatogastroenterology; 2002 Nov-Dec;49(48):1517-9
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive lymphatic fluid leakage during laparoscopic lymphnode biopsy for abdominal malignancy.
  • This report concerns massive lymphatic fluid leakage during laparoscopic abdominal lymphnode biopsy for mesenteric tumor of non-Hodgkin's disease.
  • Laparoscopic lymphnode biopsy was performed on a 58-year-old man who presented with a huge abdominal mass.
  • The initial diagnosis was based on abdominal computed tomography, which revealed a large mass.
  • This was followed by laparoscopic abdominal lymphnode biopsy for a definitive diagnosis.
  • Histological examination indicated the mass to be a B-cell type non-Hodgkin's lymphoma.
  • Hospitalization was uneventful, and the patient was discharged 7 days postoperatively to the Department of Internal Medicine for chemotherapy.
  • This new endoscopic approach offers a useful alternative to the traditional transabdominal excision of intra-abdominal lymphnodes, although attention must be paid to possible complications including massive intraoperative lymphatic leakage.
  • [MeSH-major] Abdominal Neoplasms / pathology. Biopsy / adverse effects. Laparoscopy / adverse effects. Lymph / secretion. Lymph Nodes / pathology. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397722.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • Three patients had intra-abdominal stage II, 2 patients with stage III, and 20 patients with stage IV disease.
  • There were no treatment-related deaths.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down






Advertisement